MedTrace Logo

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-04-03

No results posted yet for this study

Summary

To assess the dynamic uptake and washout of 123-I CLINDE, a potential imaging biomarker for inflammatory changes in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).

To perform blood metabolite characterization of 123-I CLINDE in healthy and subjects with AD or PD to determine the nature of metabolites in assessment of 123-I CLINDE as a single photon computed tomography (SPECT) brain imaging agent.

Evaluate the test/retest reproducibility of 123-I CLINDE, and SPECT in AD and PD subjects and healthy controls

Conditions

Interventions

DRUG

[123I]CLINDE

Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Danna L Jennings, M.D. · Institute for Neurodegenerative Disorders

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-11-01
Completion
2009-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612872 on ClinicalTrials.gov